α-Hederin promotes ferroptosis and reverses cisplatin chemoresistance in non-small cell lung cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

α-Hederin promotes ferroptosis and reverses cisplatin chemoresistance in non-small cell lung cancer

Published:2024-01-18 Issue:2 Volume:16 Page:1298-1317
ISSN:1945-4589
Container-title:Aging
language:en
Short-container-title:Aging

Author:

Han Shugao¹,Yang Xi²,Zhuang Jing²,Zhou Qing²,Wang Jingjing²,Ru Lixin²,Niu Furong³,Mao Wei⁴

Affiliation:

1. Department of Radiology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009, China

2. Huzhou Central Hospital, Affiliated Central Hospital Huzhou University, Huzhou 313000, China

3. School of Medicine, Huzhou Normal University, Huzhou 313000, China

4. Huzhou Hospital of Traditional Chinese Medicine, Zhejiang University of Traditional Chinese Medicine, Huzhou 313000, China

Publisher

Impact Journals, LLC

Reference44 articles.

1. Targeted therapy: an evolving world of lung cancer.;Mok;Respirology,2011

2. Lung cancer molecular epidemiology in China: recent trends.;Zhou;Transl Lung Cancer Res,2014

3. World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015.;McGuire;Adv Nutr,2016

4. Elderly patients with advanced NSCLC: The value of geriatric evaluation and the feasibility of CGA alternatives in predicting chemotherapy toxicity.;Barata;Pulmonology,2019

5. Targeted therapies for advanced non-small-cell lung cancer: current status and future implications.;Provencio;Cancer Treat Rev,2012

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prediction and verification of targets for α-hederin/oxaliplatin dual-loaded rHDL modified liposomes: Reversing effector T-cells dysfunction and improving anti-COAD efficiency in vitro and in vivo;International Journal of Pharmaceutics;2024-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3